

REFERENCES

1. Joy JE, Johnston RB. Multiple Sclerosis: Current status and strategies for the future. National academic press; 2001.
2. Stuve O, Oksenberg J. Multiple Sclerosis overview. 2011. Gene Reviews. May 10, 2010. <http://www.ncbi.nlm.nih.gov/pubmed/20301492>.
3. National MS society. 2011. National MS Society. June 4 2010. Natmsociety.org.
4. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. *Ann Neurol*. 2001;50: 121–7.
5. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. *Neurology*. 1998; 51(3):682-9.
6. Keith AB, Arnon R, Teitelbaum D, Caspary EA, Wisniewski HM. The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. *J Neurol Sci*. 1979;42: 267–74.
7. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. *Eur J Immunol*. 1971;1:242–8.
8. Teitelbaum D, Webb C, Meshorer A, Arnon R, Sela M. Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. *Eur J Immunol*. 1973;3: 273–9.

9. Teitelbaum D, Webb C, Bree M, Meshorer A, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. *Clin Immunol Immunopathol.* 1974;3: 256–62.
10. Abramsky O, Teitelbaum D, Arnon R. Effect of a synthetic polypeptide (COP 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis: Preliminary report. *J Neurol Sci.* 1977; 31: 433–8.
11. Bornstein MB, Miller AI, Teitelbaum D, Arnon R, Sela M. Multiple sclerosis: trial of a synthetic polypeptide. *Ann Neurol.* 1982 ;11: 317–9.
12. Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, Myers LW, Panitch HS, Pruitt A, Rose JW, Kachuck N, Wolinsky JS. Copolymer 1 Multiple Sclerosis Study Group. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. *Mult Scler.* 2000; 6: 255–66.
13. Johnson KP., Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB. The Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, doubleblind placebo-controlled trial. *Neurology.* 1995;45:1268–76.
14. Ffrench-Constant C. Pathogenesis of multiple sclerosis. *Lancet.* 1994;343:271-5.
15. Hemler ME, Sanchez-Madrid F, Flotte TJ, et al. Glycoproteins of 210,000 and 130,000 m.w. on activated T cells: cell distribution and antigenic relation to components on resting cells and T cell lines. *J Immunol.* 1984;132:3011-8.

16. Lobb RR, Hemler ME. The pathophysiologic role of alpha 4 integrins in vivo. *J Clin Invest.* 1994;94:1722-8.
17. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr. Surface expression of $\alpha 4$ integrin by CD4 T cells is required for their entry into brain parenchyma. *J Exp Med.* 1993;177:57-68.
18. Elices MJ, Osborn L, Takada Y, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. *Cell.* 1990;60:577-84.
19. Carlos TM, Schwartz BR, Kovach NL, et al. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. *Blood.* 1990;76:965-70 [Erratum, *Blood* 1990;76:2420.].
20. Bayless KJ, Meininger GA, Scholtz JM, Davis GE. Osteopontin is a ligand for the $\alpha 4\beta 1$ integrin. *J Cell Sci.* 1998;111:1165-1174.
21. Chris H. Polman, M.D. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. *N Engl J Med.* 2006; 354:899-910.
22. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. *Annu Rev Immunol.* 1992; 10:153-87.
23. Barcellos LF, Sawcer S, Ramsay PP, Baranzini SE, Thomson G, Briggs F, Cree BC, Begovich AB, Villoslada P, Montalban X, Uccelli A, Savettieri G, Lincoln RR, DeLoa C, Haines JL, Pericak-Vance MA, Compston A, Hauser SL, Oksenberg J. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. *Hum Mol Genet.* 2006;15: 2813-24.

24. Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A, Caillier SJ, Ban M, Goris A, Barcellos LF, Lincoln R, McCauley JL, Sawcer SJ, Compston DA, Dubois B, Hauser SL, Garcia-Blanco M.A, Pericak-Vance MA, Haines JL. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. *Nat Genet.* 2007; 39: 1083-91.
25. Hafler DA, Saadeh MG, Kuchroo VK, Milford E, Steinman L. TCR usage in human and experimental demyelinating disease. *Immunol Today.* 1996;17: 152-9.
26. Hartung HP. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. *Lancet.* 2002; 360: 2018-25.
27. Einstein ER, Robertson DM, Dicaprio JM, Moore W. The isolation from bovine spinal cord of a homogeneous protein with encephalitogenic activity. *J Neurochem.* 1962; 9: 353-61.
28. Lebar R, Lubetzki C, Vincent C, Lombraill P, Boutry JM. The M2 autoantigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. *Clin Exp Immunol.* 1986;66: 423-34.
29. Tuohy VK, Lu ZJ, Sobel RA, Laursen RA, Lees MB. A synthetic peptide from myelin proteolipid protein induces experimental allergic encephalomyelitis. *J Immunol.* 1988;141:1126-30.
30. Wekerle H, Immunopathogenesis of multiple sclerosis. *Acta Neurol (Napoli).* 1991; 13:197-204.

31. Pettinelli CB, McFarlin DE. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. *J Immunol.* 1981; 127:1420-3.
32. Renno T, Krakowski M, Piccirillo C, Lin JY, Owens T. TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. Regulation by Th1 cytokines. *J Immunol.* 1995;154: 944-53.
33. Gutcher I, Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. *J Clin Invest.* 2007; 117: 1119-27.
34. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, Klonowski P, Austin A, Lad N, Kaminski N, Galli SJ, Oksenberg JR, Raine CS, Heller R, Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. *Nat Med.* 2002; 8: 500-8.
35. Traugott U, Reinherz EL, Raine CS. Multiple sclerosis: distribution of T cell subsets within active chronic lesions. *Science.* 1983 ; 219: 308-10.
36. Babbe H, Roers A, Waisman A, Lassmann H, Goebels N, Hohlfeld R, Friese M, Schroder R, Deckert M, Schmidt S, Ravid R, Rajewsky K. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. *J Exp Med.* 2000;192: 393-404.

37. Monteiro J, Hingorani R, Peroglizzi R, Apatoff B, Gregersen PK. Oligoclonality of CD8+ T cells in multiple sclerosis. *Autoimmunity*. 1996; 23: 127-38.
38. Crawford MP, Yan SX, Ortega SB, Mehta RS, Hewitt RE, Price DA, Stastny P, Douek DC, Koup RA, Rucke MK, Karandikar NJ. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. *Blood*. 2004;103: 4222-31.
39. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. *J Exp Med*. 2001;194: 669-76.
40. Steinman L. Myelin-specific CD8 T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis. *J Exp Med*. 2001; 194: F27-30.
41. Sun D, Whitaker JN, Huang Z, Liu D, Coleclough C, Wekerle H, Raine CS. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. *J Immunol*. 2001; 166:7579-87.
42. York NR, Mendoza JP, Ortega SB, Benagh A, Tyler AF, Firan M, Karandikar NJ. Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis. *J Autoimmun*. 2010; 35: 33-44.
43. Baughman EJ, Mendoza JP, Ortega SB, Ayers CL, Greenberg BM, Frohman EM, Karandikar NJ. Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of Multiple Sclerosis. *J Autoimmun*. 2010;36:115-24.

44. Gran B, Gestri D, Sottini A, Roldan Q, et. al. Detection of skewed T-cell receptor V-beta gene usage in the peripheral blood of patients with multiple sclerosis. *J Neuroimmunol.* 1998; 85:22-32.
45. Kotzin BL, Karuturi S, Chou YK, Lafferty J, Forrester JM, Better M, Nedwin GE, Offner H, Vandembark AA. Preferential T-cell receptor beta-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis. *Proc Natl Acad Sci USA.* 1991;88: 9161-5.
46. Musette P, Bequet D, Delarbre C, Gachelin G, Kourilsky P, Dormont D. Expansion of a recurrent V beta 5.3+ T-cell population in newly diagnosed and untreated HLA-DR2 multiple sclerosis patients. *Proc Natl Acad Sci USA.* 1996;93:12461-6.
47. Wucherpfennig KW, Newcombe J, Li H, Keddy C, Cuzner ML, Hafler DA. T cell receptor V alpha-V beta repertoire and cytokine gene expression in active multiple sclerosis lesions. *J Exp Med.* 1992;175: 993-1002.
48. Jacobsen M, Cepok S, Quak E, Happel M, Gaber R, Ziegler A, Schock S, Oertel WH, Sommer N, Hemmer B. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. *Brain.* 2002; 125: 538-50.
49. Matsumoto Y, Yoon WK, Jee Y, Fujihara K, Misu T, Sato S, Nakashima I, Itoyama Y. Complementarity-determining region 3 spectratyping analysis of the TCR repertoire in multiple sclerosis. *J Immunol.* 2003; 170: 4846-53.

50. Muraro PA, Cassiani-Ingoni R, Chung K, Packer AN, Sospedra M, Martin R. Clonotypic analysis of cerebrospinal fluid T cells during disease exacerbation and remission in a patient with multiple sclerosis. *J Neuroimmunol.* 2006; 171:177-83.
51. Karandikar NJ, Crawford MP, Yan X, Ratts RB, Brenchley JM, Ambrozak DR, Lovett-Racke AE, Frohman EM, Stastny P, Douek DC, Koup RA, Racke MK. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. *J Clin Invest.* 2002;109: 641-9.
52. Douek DC, Betts MR, Brenchley JM, Hill BJ, Ambrozak DR, Ngai KL, Karandikar NJ, Casazza JP, Koup RA. A novel approach to the analysis of specificity, clonality, and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape. *J Immunol.* 2002; 168: 3099-104.
53. Biegler BW, Yan SX, Ortega SB, Tennakoon DK, Racke MK, Karandikar NJ. Glatiramer acetate (GA) therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis. *J Neuroimmunol.* 2006;180: 159-71.
54. Lefranc MP. IMGT, the international ImMunoGeneTics database. *Nucleic Acids Res.* 2001; 29: 207-9.
55. Lefranc MP. IMGT, the International ImMunoGeneTics Information System, *Methods Mol Biol.* 2001; 248: 27-49.

56. Warren R., Freeman, J., Zeng T., Holt R., Exhaustive T-cell repertoire sequencing of human peripheral blood samples reveals signatures of antigen selection and a directly measured repertoire size of at least 1 million clonotypes. *Genome Res.* 2011, 21: 790-797
57. Junker, A., Ivanidze, J., Malotka, J., Eiglmeier, I., Lassmann, H., Wekerle, H., Meinl, E., Hohlfeld, R., Dornmair, K., 2007. Multiple sclerosis: T-cell receptor expression in distinct brain regions. *Brain* 130, 2789-2799.
58. Li, Y., Uccelli, A., Laxer, K.D., Jeong, M.C., Vinters, H.V., Tourtellotte, W.W., Hauser, S.L., Oksenberg, J.R., 1997. Local-clonal expansion of infiltrating T lymphocytes in chronic encephalitis of Rasmussen. *J Immunol* 158, 1428-1437.
59. Ria, F., van den Elzen, P., Madakamutil, L.T., Miller, J.E., Maverakis, E., Sercarz, E.E., 2001. Molecular characterization of the T cell repertoire using immunoscope analysis and its possible implementation in clinical practice. *Curr Mol Med* 1, 297-304.
60. Batliwalla, F., Monteiro, J., Serrano, D., Gregersen, P.K., 1996. Oligoclonality of CD8+ T cells in health and disease: aging, infection, or immune regulation? *Hum Immunol* 48, 68-76.
61. Tennakoon, D.K., Mehta, R.S., Ortega, S.B., Bhoj, V., Racke, M.K., Karandikar, N.J., 2006. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. *J Immunol* 176, 7119-7129.

62. Laplaud, D.A., Ruiz, C., Wiertlewski, S., Brouard, S., Berthelot, L., Guillet, M., Melchior, B., Degauque, N., Edan, G., Brachet, P., Damier, P., Soullillou, J.P., 2004. Blood T-cell receptor beta chain transcriptome in multiple sclerosis. Characterization of the T cells with altered CDR3 length distribution. *Brain* 127, 981-995.
63. Somma, P., Ristori, G., Battistini, L., Cannoni, S., Borsellino, G., Diamantini, A., Salvetti, M., Sorrentino, R., Fiorillo, M.T., 2007. Characterization of CD8+ T cell repertoire in identical twins discordant and concordant for multiple sclerosis. *J Leukoc Biol* 81, 696-710.
64. Bourdette, D.N., Whitham, R.H., Chou, Y.K., Morrison, W.J., Atherton, J., Kenny, C., Liefeld, D., Hashim, G.A., Offner, H., Vandenberg, A.A., 1994. Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides. *J Immunol* 152, 2510-2519.
65. Skulina, C., Schmidt, S., Dornmair, K., Babbe, H., Roers, A., Rajewsky, K., Wekerle, H., Hohlfeld, R., Goebels, N., 2004. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. *Proc Natl Acad Sci U S A* 101, 2428-2433.
66. Janeway, C A, Travers, P, Walport, M, Shlomchik, J. *Immunobiology*. 5th edition. Garland Science 2001
67. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. *Neurology* [1998, 51(3):682-9]

68. Agrawal SM, Silva C, Tourtellotte WW, Yong VW. EMMPRIN: a novel regulator of leukocyte transmigration into the CNS in multiple sclerosis and experimental autoimmune encephalomyelitis. *J Neurosci*. 2011;31(2):669-77.
69. Stockinger H, Ebel T, Hansmann C, Koch C. *Leukocyte Typing VI*. Garland publishing, 2002.
70. Martiniet W, Schriviers DM, Kockx MM. Nucleofection as an efficient nonviral transfection method for human monocytic cells. *Biotechnol Lett*. Jul;25(13):1025-9
71. Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, Nabeshima K. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. *Cancer Res*. 1995; 55(2):434-9.
72. Miyauchi T, Kanekura T, Yamaoka A, Ozawa M, Miyazawa S, Muramatsu T. Basigin, a new, broadly distributed member of the immunoglobulin superfamily, has strong homology with both the immunoglobulin V domain and the beta-chain of major histocompatibility complex class II antigen. *J Biochem (Tokyo)* 1990; 107:316–23.
73. Fossum S, Mallett S, Barclay AN. The MRC OX-47 antigen is a member of the immunoglobulin superfamily with an unusual transmembrane sequence. *Eur. J. Immunol*. 1991; 21:671-9.
74. Schlosshauer B, Herzog KH. Neurothelin: an inducible cell surface glycoprotein of blood-brain barrier-specific endothelial cells and distinct neurons. *J Cell Biol*. 1990;110:1261-74.

75. Altruda F, Cervella P, Gaeta ML, Daniele A, Giancotti F, Tarone G, Stefanuto G, Silengo L. Cloning of cDNA for a novel mouse membrane glycoprotein (gp42): shared identity to histocompatibility antigens, immunoglobulins and neural-cell adhesion molecules. *Gene*. 1989;85(2):445-51.
76. Hanna SM, Kirk P, Holt OJ, Puklavec MJ, Brown mH, Barclay AN. A novel form of the membrane protein CD147 that contains an extra Ig-like domain and interacts homophilically. *BMC Biochem*. 2003; 4:17.
77. Tang W, Chang SB, Hemler ME. Links between CD147 function, glycosylation, and caveolin-1. *Mol Biol Cell*. 2004;15(9):4043-50.
78. Yurchenko V, Constant S, Bukrinsky M. Dealing with the family: CD147 interactions with cyclophilins. *Immunology*. 2006;117:301-9.
79. Jiang J, Tang J. CD147 and its interacting proteins in cellular functions. *Acta Physiologica Sinica*. 2007;59(4):517-23.
80. Seulberger H, Lottspeich F, Risau W. The inducible blood brain barrier specific molecule HT7 is a novel immunoglobulin-like cell surface glycoprotein. *Embo J*. 1990;9(7): 2151-8.
81. Ellis SM, Nabeshima K, Biswas C. Monoclonal antibody preparation and purification of a tumor cell collagenase-stimulatory factor. *Cancer Res*. 1989;49(12):3385-91.
82. Sameshima T, Nabeshima K, Toole BP et al Glioma cell extra-cellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. *Cancer Lett*. 2000;157:177-84.

83. Kataoka H, DeCastro R, Zucker S, Biswas C. Tumor cell- derived collagenase-stimulatory factor increases expression of interstitial collagenase stromolysin and 72-kDa gelatinase. *Cancer Res* 1993; 53: 3154–8.
84. Tang Y, Kesavan P, Nakada MT, Yan L. Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. *Mol Cancer Res*. 2004;2(2):73-80.
85. Kanekura T, Chen X, Kanzaki T. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. *Int J Cancer*. 2002;99(4):520-8.
86. Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiyaand J, Kikuchi M. Emmprin (basigin/CD147): Matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. *Pathol International*. 2006; 56: 359–67.
87. Tang Y, Nakada MT, Kesavan P, McCabe F, Millar H, Rafferty P, Bugelski P, Yan L. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. *Cancer Res*. 2005;65(8):3193-9.
88. Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O, Wandler N, Passlick B, Huber RM, Schlimok G, Baeuerle PA, Riethmüller G. Combined transcriptome and genome analysis of single micrometastatic cells. *Nat Biotechnol*. 2002;20(4):387-92.

89. Sameshima T, Nabeshima K, Toole BP et al. Expression of emmprin (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas. *Int J Cancer*. 2000; 88: 21–7.
90. Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. *Clin Exp Metastasis*. 2003; 20: 161–9.
91. van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. *Am J Pathol*. 1997; 151: 665–70.
92. Liu F, Zhang Y, Chen L, Wang Y, Fan Y, Lei T, Gu F, Lang R, Pringle GA, Zhang X, Chen Z, Fu L. Expression of Hab18G is associated with tumor progression and prognosis of breast carcinoma. *Breast Cancer Res Treat*. 2010; 124(3):677-88
93. Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN and Halestrap AP. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression *EMBO J*. 2000; 19(15): 3896–904.
94. Yoshida S, Shibata M, Yamamoto S, Hagihara M, Asai N, Takahashi M, Mizutani S, Muramatsu T, Kadomatsu K. Homo-oligomer formation by basigin, an immunoglobulin superfamily member, via its N-terminal immunoglobulin domain. *Eur J Biochem* 2000; 267(14): 4372-80.

95. Gallagher SM, Castorino JJ, Wang D, Philp NJ. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. *Cancer Res.* 2007; 67(9): 4182-9.
96. Deora AA, Philp N, Hu J, Bok D, Rodriguez-Boulan E. Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone CD147 in kidney and retinal epithelia. *Proc Natl Acad Sci USA.* 2005;102(45): 16245-50.
97. Berditchevski F, Chang S, Bodorova J, Hemler ME. Generation of monoclonal antibodies to integrin-associated proteins. Evidence that alpha3beta1 complexes with EMMPRIN/basigin/OX47/M6. *J Biol Chem.* 1997;272(46):29174-80.
98. Kasinrerak W, Fiebinger E, Stefanova I, Baumruker T, Stockinger H. Human leukocyte activation antigen M6, a member of the Ig superfamily, is the species homologue of rat OX-47, mouse basigin, and chicken HT7 molecule. *J. Immunol.* 1992;149:847-54.
99. Khunkeawla P, Moonsom S, Staffler G, Kongtawelert P, Kasinrerak W. Engagement of CD147 molecule-induced cell aggregation through the activation of protein kinases and reorganization of the cytoskeleton. *Immunobiol.* 2001;203(4):659-69.
100. Woodhead VE, Stonehouse TJ, Binks MH, Speidel K, Fox DA, Gaya A, Hardie D, Henniker AJ, Horejsi V, Sagawa K, Skubitz KM, Taskov H, Todd RF 3rd, van Agthoven A, Katz DR, Chain BM. Novel molecular mechanisms of dendritic cell-induced T cell activation. *Int Immunol.* 2000;12(7):1051-61.

101. Qian AR, Zhang W, Cao JP, Yang PF, Gao X, Wang Z, Xu HY, Weng YY, Shang P. Downregulation of CD147 expression alters cytoskeleton architecture and inhibits gelatinase production and SAPK pathway in human hepatocellular carcinoma cells. *J Exp Clin Cancer Res.* 2008;27:50.
102. Arora K, Gwinn WM, Bower MA, Watson A, Okwumabua I, MacDonald HR, Bukrinsky MI, Constant SL. Extracellular cyclophilins contribute to the regulation of inflammatory responses. *J Immunol.* 2005;175(1):517-22.
103. Xu Q, Leiva MC, Fischkoff SA, Handschumacher RE, Lyttle CR. Leukocyte chemotactic activity of cyclophilin. *J Biol Chem.* 1992;267(17):11968-71.
104. Sherry B, Yarlett N, Strupp A, Cerami A. Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. *Proc Natl Acad Sci USA.* 1992;89(8):3511-5.
105. Damsker JM, Okwumabua I, Pushkarsky T, Arora K, Bukrinsky MI, Constant SL. Targeting the chemotactic function of CD147 reduces collagen-induced arthritis. *Immunology.* 2009;126(1):55-62.
106. Allain F, Vanpouille C, Carpentier M, Slomianny MC, Durieux S, Spik G. Interaction with glycosaminoglycans is required for cyclophilin B to trigger integrin-mediated adhesion of peripheral blood T lymphocytes to extracellular matrix. *Proc Natl Acad Sci USA.* 2002;99(5):2714-9.
107. Pushkarsky T, Yurchenko V, Vanpouille C, Brichacek B, Vaisman I, Hatakeyama S, Nakayama KI, Sherry B, Bukrinsky MI. Cell surface expression of CD147/EMMPRIN is regulated by cyclophilin 60. *J Biol Chem.* 2005;280(30):27866-71.

108. Yurchenko V, Pushkarsky T, Li JH, Dai WW, Sherry B, Bukrinsky M. Regulation of CD147 cell surface expression: involvement of the proline residue in the CD147 transmembrane domain. *J Biol Chem.* 2005;280(17):17013-9.
109. Huet E, Vallée B, Szul D, Verrecchia F, Mourah S, Jester JV, Hoang-Xuan T, Menashi S, Gabison EE. Extracellular matrix metalloproteinase inducer/CD147 promotes myofibroblast differentiation by inducing alpha-smooth muscle actin expression and collagen gel contraction: implications in tissue remodeling. *FASEB J.* 2008;22(4):1144-54.
110. Koch C, Staffler G, Hüttinger R, Hilgert I, Prager E, Cerný J, Steinlein P, Majdic O, Horejsí V, Stockinger H. T cell activation-associated epitopes of CD147 in regulation of the T cell response, and their definition by antibody affinity and antigen density. *Int Immunol.* 1999;11(5):777-86.
111. Chiampanichayakul S, Peng-in P, Khunkaewla P, Stockinger H, Kasinrerak W. CD147 contains different bioactive epitopes involving the regulation of cell adhesion and lymphocyte activation. *Immunobiol.* 2006;211(3):167-78
112. Chen X, Su J, Chang J, Kanekura T, Li J, Kuang YH, Peng S, Yang F, Lu H, Zhang JL. Inhibition of CD147 gene expression via RNA interference reduces tumor cell proliferation, activation, adhesion, and migration activity in the human Jurkat T-lymphoma cell line. *Cancer Invest.* 2008;26(7):689-97.

113. Pistol G, Matache C, Calugaru A, Stavaru C, Tanaseanu S, Ionescu R, Dumitrache S, Stefanescu M. Roles of CD147 on T lymphocytes activation and MMP-9 secretion in systemic lupus erythematosus. *J Cell Mol Med.* 2007;11(2):339-48.
114. Khunkaewla P, Schiller HB, Paster W, Leksa V, et. al. LFA-1 mediated leukocyte adhesion regulated by interaction of CD43 with LFA-1 and CD147. *Mol Immunol.* 2008;45:1703–11.
115. Staffler G, Szekeres A, Schultz GJ, Saemann MD, Prager E, Zeyda M, Drbal K, Zlabinger GJ, Stulnig TM, Stockinger H. Selective inhibition of T cell activation via CD147 through novel modulation of lipid rafts. *J. Immunol.* 2003;171:1707–14.
116. Lyons, A.B. 2000. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. *J Immunol. Methods.* 243:147–154.
117. Brenchley, J. M., N. J. Karandikar, M. R. Betts, D. R. Ambrozak, B. J. Hill, L. E. Crotty, J. P. Casazza, J. Kuruppu, S. A. Migueles, M. Connors, M. Roederer, D. C. Douek, and R. A. Koup. 2003. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. *Blood* 101:2711-2720.
118. Parks, D. R., M. Roederer, and W. A. Moore. 2006. A new "Logicle" display method avoids deceptive effects of logarithmic scaling for low signals and compensated data. *Cytometry A.*

119. Herzenberg, L. A., J. Tung, W. A. Moore, L. A. Herzenberg, and D. R. Parks. 2006. Interpreting flow cytometry data: a guide for the perplexed. *Nat Immunol* 7:681-685.
120. Hillman, A., Dunne, E., Kenny, D. cDNA amplification by SMART-PCR and suppression subtractive hybridization PCR. *Methods in Molecular Biology* 2009;496:223-43.
121. Zhu YY, Machleder EM, Chenchik A, Li R, Siebert PD. Reverse transcriptase template switching: a SMART approach for full-length cDNA library construction. *Biotechniques*. 2001;30:892–897.
122. Schaefer, BC. Revolutions in rapid amplification of cDNA ends: new strategies for polymerase chain reaction cloning of full-length cDNA ends. *Anal Biochem*. 1995 May 20;227(2):255-73
123. Kirsch, A. H., Diaz, L. A., Jr, Bonish, B., Antony, P. A. and Fox, D. A. 1997. The pattern of expression of CD147/neurothelin during human T-cell ontogeny as defined by the monoclonal antibody 8D6. *Tissue Antigens* 50:147.
124. Ruiz, S., Castro-Castro, A., Bustelo, X. CD147 inhibits the nuclear factor of activated T cells by impairing Vav1 and Rac1 downstream signaling. *J Biol Chem*. 2008 Feb 29;283(9):5554-66
125. Luo J, Teplyakov A, Obmolova G et al. Structure of the EMMPRIN N-terminal domain 1: dimerization via beta-strand swapping. *Proteins* 2009; 77:1009–14.

126. Igakura T, Kadomatsu K, Taguchi O et al. Roles of basigin, a member of the immunoglobulin superfamily, in behavior as to an irritating odor, lymphocyte response, and blood-brain barrier. *Biochem Biophys Res Commun* 1996; 224:33–6.
127. Jurgens, L., Khanna, R., Weber, J., Rimas, J. Transduction of primary lymphocytes with Epstein-barr virus latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells. *J Clin Immunol*. 2006 Jan, 26(1)
128. Ebert, O., et al. (1997). Lymphocyte apoptosis: induction by gene transfer techniques. *Gene Ther*. 4: 296.
129. Egawa N, Koshikawa N, Tomari T, Nabeshima K, Isobe T, Seiki M. Membrane Type 1 matrix metalloproteinase (MT1-MMP/MMP-14) cleaves and releases a 22-kDa extracellular matrix metalloproteinase inducer (EMMPRIN) fragment from tumor cells. *J Biol Chem* 2006; 281:37576–85.
130. Brabletz, T., Pfeuffer, I., Schorr, E., Siebelt, F., Wirth, T., and Serfling, E. (1993) Transforming growth factor and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site. *Mol. Cell. Biol.* 13, 1155–1162
131. Chen, W., Jin, W., Hardegen, N., Lei, K.J., Li, L., Marinos, N., McGrady, G., and Wahl, S.M. Conversion of peripheral CD4⁺CD25⁻ naive T cells to CD4⁺CD25⁺ regulatory T cells by TGF-beta induction of transcription factor Foxp3. *J. Exp. Med.* (2003) 198,1875-1886

132. Li, M.O., Wan, Y.Y., and Flavell, R.A. Tcell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. *Immunity* 26, 579-591
133. Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG, Roberts AB. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. *J Cell Sci.* 2005 May 15;118(Pt 10):2143-53.
134. Hsieh HL, Wang HH, Wu WB, Chu PJ, Yang CM. Transforming growth factor- β 1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK- and JNK-NF- κ B pathways. *J Neuroinflammation.* 2010 Dec 6;7:88.
135. Yuan, W., and Varga, J. Transforming growth factor repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. *J. Biol. Chem.* (2001) 276, 38502–38510
136. Werner, F., Jain, M.K., Feinberg, M.W., Sibinga, N.E., Pellacani, A., Wiesel, P., Chin, M.T., Topper, J.N., Perrella, M.A., and Lee, M.E. (2000) Transforming growth factor-b1 inhibition of macrophage activation is mediated via Smad3. *J. Biol. Chem.* 275, 36653-36658
137. Maryanski J.L., Jongeneel C.V., Bucher P., Casanova J.-L., Walker P.R. Single-cell PCR analysis of TCR repertoires selected by antigen in vivo: A high magnitude CD8 response is comprised of very few clones (1996) *Immunity*, 4 (1), pp. 47-55.

138. Gillett A, Thessen Hedreul M, Khademi M, Espinosa A, Beyeen AD, Jagodic M, Kockum I, Harris RA, Olsson T. Interleukin 18 receptor 1 expression distinguishes patients with multiple sclerosis. *Mult Scler*. 2010 Sep;16(9):1056-65.
139. Wang C, Sanders CM, Yang Q, Schroeder HW Jr, Wang E, Babrzadeh F, Gharizadeh B, Myers RM, Hudson JR Jr, Davis RW, Han J. High throughput sequencing reveals a complex pattern of dynamic interrelationships among human T cell subsets. *Proc Natl Acad Sci U S A*. 2010 Jan 26;107(4):1518-23.
140. Robins HS, Campregher PV, Srivastava SK, Wacher A, Turtle CJ, Kabsai O, Riddell SR, Warren EH, Carlson CS. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. *Blood*. 2009 Nov 5;114(19):4099-107.
141. Robins, H., Srivastava, S., Campregher, P., Turtle, C., Anddreisen, J. Overlap and effective size of the human CD8+ T-cell receptor repertoire. *Sci Transl Med*, 2:47 ra 64